#Ocrelizumab – How Ocrelizumab Works

admin avatar

by admin |

Share this article:

Share article via email

news-33

Ocrelizumab, an anti-CD20 monoclonal antibody, targets mature B-cells. Almost 95% of the B-cell population has these antigenic epitopes after maturation and does not shed them, which is what makes it a potent marker for therapeutic purposes (cancer being a very common area of interest in this regard).

Read more about Ocrelizumab here: http://bit.ly/1JUBLqj

The Multiple Sclerosis Podcast



Video